As of 2024-12-15, the Relative Valuation of Keros Therapeutics Inc (KROS) is (100.40) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.83 USD, the upside of Keros Therapeutics Inc based on Relative Valuation is -633.2%.
The range of the Relative Valuation is (92.87) - (86.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.7x - 31.0x | 25.8x |
| Forward P/E multiples | 18.7x - 19.2x | 19.0x |
| Fair Price | (92.87) - (86.15) | (100.40) |
| Upside | -593.2% - -557.5% | -633.2% |
| Date | P/E |
| 2024-12-03 | -13.79 |
| 2024-12-02 | -12.66 |
| 2024-11-29 | -12.88 |
| 2024-11-27 | -13.06 |
| 2024-11-26 | -12.80 |
| 2024-11-25 | -12.62 |
| 2024-11-22 | -12.48 |
| 2024-11-21 | -12.01 |
| 2024-11-20 | -12.08 |
| 2024-11-19 | -11.96 |
| 2024-11-18 | -12.05 |
| 2024-11-15 | -12.63 |
| 2024-11-14 | -13.46 |
| 2024-11-13 | -14.07 |
| 2024-11-12 | -14.48 |
| 2024-11-11 | -15.20 |
| 2024-11-08 | -15.15 |
| 2024-11-07 | -14.99 |
| 2024-11-06 | -14.83 |
| 2024-11-05 | -13.96 |
| 2024-11-04 | -13.38 |
| 2024-11-01 | -13.37 |
| 2024-10-31 | -12.95 |
| 2024-10-30 | -13.31 |
| 2024-10-29 | -13.42 |
| 2024-10-28 | -13.55 |
| 2024-10-25 | -13.56 |
| 2024-10-24 | -13.29 |
| 2024-10-23 | -12.94 |
| 2024-10-22 | -13.24 |
| 2024-10-21 | -13.45 |
| 2024-10-18 | -13.67 |
| 2024-10-17 | -13.63 |
| 2024-10-16 | -13.87 |
| 2024-10-15 | -13.47 |
| 2024-10-14 | -13.50 |
| 2024-10-11 | -13.34 |
| 2024-10-10 | -12.89 |
| 2024-10-09 | -12.93 |
| 2024-10-08 | -13.31 |
| 2024-10-07 | -13.41 |
| 2024-10-04 | -13.59 |
| 2024-10-03 | -13.36 |
| 2024-10-02 | -13.68 |
| 2024-10-01 | -13.34 |
| 2024-09-30 | -12.96 |
| 2024-09-27 | -12.59 |
| 2024-09-26 | -12.69 |
| 2024-09-25 | -12.59 |
| 2024-09-24 | -12.40 |